Tag Archives: PDE4 inhibitor

March, 2017

• 6 March

  Celgene’s Oral Otezla Demonstrates Positive Results in Study of Psoriasis Patients Naïve to Systemic and Biologic Therapy

  

  SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ:CELG) today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate plaque psoriasis with a body surface area (BSA) of 5-10 percent, were presented at the American Academy of Dermatology’s …

  Share

  • Facebook
  • Twitter
  • LinkedIn

May, 2016

• 16 May

  Pfizer to Purchase Anacor in $5.2 Billion Deal

  

  Pfizer Inc. (NYSE:PFE) and Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s …

  Share

  • Facebook
  • Twitter
  • LinkedIn